Circulating nucleosomes and response to chemotherapy:: An in vitro, in vivo and clinical study on cervical cancer patients

被引:52
|
作者
Trejo-Becerril, C
Pérez-Cárdenas, E
Treviño-Cuevas, H
Taja-Chayeb, L
García-López, P
Segura-Pacheco, B
Chávez-Blanco, AC
Lizano-Soberon, M
González-Fierro, A
Mariscal, I
Wegman-Ostrosky, T
Dueñas-González, A
机构
[1] INCAN, IIB, Unidad Invest Biomed Canc, Mexico City, DF, Mexico
[2] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mexico City, DF, Mexico
关键词
circulating nucleosomes; ELISA; cervical cancer; neoadjuvant chemotherapy;
D O I
10.1002/ijc.11003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It is known that cell-free DNA circulates in plasma/serum of patients with cancer and that part of this DNA circulates as nucleosomes that can be quantified by ELISA. We analyzed the effect of tumor and chemotherapy upon the levels of nucleosomes in vitro, in vivo and in cervical cancer patients. The levels of nucleosomes pre- and post-treatment were correlated with response in I I patients receiving chemotherapy. Nucleosomes were determined in nude mice treated with or without cisplatin and carrying tumors generated with HeLa cells, and in the cell lysate and supernatant of HeLa cells exposed to cisplatin in culture. In addition, nucleosomes were determined at different time points in patients and in rats receiving chemotherapy. Nucleosomes were higher in patients that controls (1,760 vs. 601, p = 0.0001). After 24 hr of treatment with oxaliplatin and gemcitabine, the levels decreased in 6 patients of whom Shad response. Nucleosome levels differed between mice xenografted and not xenografted (765 vs. 378, p = 0.001) and between xenografted treated with or without cisplatin (650 vs. 765, p = 0.010), but not in tumor-free animals treated and untreated with cisplatin (378 vs. 379, p = 0.99). In vitro, nucleosomes reached at peak 8 hr in cell lysates to decrease thereafter, whereas in supernatant, levels continued to increase up to 24 hr. Serial determination of nucleosomes in patients showed a rise within 6-12 hr and then a reduction to below the basal at 24 hr. In rats, nucleosomes had no major changes in those receiving oxaliplatin or the triple combination of cisplatin, gemcitabine and paclitaxel as compared to untreated controls. An overdose of this triple combination produced a transient elevation of almost 1,000 AU over the basal. Our results demonstrate that most of circulating nucleosomes originate from the tumor and that chemotherapy produces an early rise most likely due to, tumor apoptosis and that nucleosomes are rapidly cleared from circulation. On the contrary, chemotherapy within the therapeutic range of doses has no effect on nucleosome levels in healthy mice and,rats. This data suggests that the determination of circulating nucleosomes pre- and post-treatment could be a useful test to predict response to chemotherapy in cancer patients. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:663 / 668
页数:6
相关论文
共 50 条
  • [21] Study on the effect and mechanism of NFKBIA on cervical cancer progress in vitro and in vivo
    Chen, Mengyue
    Liang, Xiaolong
    Liang, Zhiqing
    Zhao, Limei
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2021, 47 (11) : 3931 - 3942
  • [22] A metabolomics approach for predicting the response to neoadjuvant chemotherapy in cervical cancer patients
    Hou, Yan
    Yin, Mingzhu
    Sun, Fengyu
    Zhang, Tao
    Zhou, Xiaohua
    Li, Huiyan
    Zheng, Jian
    Chen, Xiuwei
    Li, Cong
    Ning, Xiaoming
    Lou, Ge
    Li, Kang
    MOLECULAR BIOSYSTEMS, 2014, 10 (08) : 2126 - 2133
  • [23] In vitro and In vivo characterization of circulating tumor cells from breast cancer patients
    Jalla, Sanjoo
    Chen, Xioru
    Burke, Patricia
    Shi, Xiaoqing
    Czapiga, Meggan
    Datta, Vivekananda
    Brohawn, Philip
    Huang, Jiaqi
    Brown, Charles
    Hurt, Elaine
    Richman, Laura
    Hollingsworth, Robert
    LaVallee, Theresa
    Bao, Haifeng
    CANCER RESEARCH, 2013, 73 (08)
  • [24] Pattern of in vitro chemotherapy response in pancreatic cancer and its clinical implication
    Franko, J.
    Bilimoria, M. M.
    Chalikonda, S.
    Lannitti, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [25] Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer
    Lissoni, P
    Rovelli, F
    Malugani, F
    Brivio, F
    Fumagalli, L
    Gardani, GS
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2003, 18 (02): : 152 - 155
  • [26] Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer
    Zhu, Wenjie
    Liu, Mei
    Fan, Ying
    Ma, Fei
    Xu, Ningzhi
    Xu, Binghe
    CANCER MEDICINE, 2018, 7 (09): : 4420 - 4433
  • [27] CHEMOTHERAPY FOR CERVICAL CANCER PATIENTS: IS IT A "NIGHTMARE"?
    Suwendar
    Fudholi, Achmad
    Andayani, Tri Murti
    Sastramihardja, Herri S.
    JOURNAL OF ENGINEERING SCIENCE AND TECHNOLOGY, 2021, 16 (01): : 209 - 223
  • [28] Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study
    Xiao, Yan
    Cheng, Huijun
    Wang, Li
    Yu, Xiao
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2020, 31 (01)
  • [29] Cellular response to chemotherapy and radiation in cervical cancer
    Saxena, A
    Yashar, C
    Taylor, DD
    Gercel-Taylor, C
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 192 (05) : 1399 - 1403
  • [30] Clinical response and safety of apatinib monotherapy in recurrent or metastatic cervical cancer after failure of chemotherapy: An observational study
    Xiao, Y.
    Cheng, H.
    Yu, X.
    Wang, L.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 232 - 232